Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L)

BACKGROUND: Bevacizumab, a humanized antibody to vascular endothelial growth factor (VEGF), shows clinical activity against human cancer, with its addition to standard chemotherapy having been found to improve outcome in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). However,...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Takeda, Masayuki, Okamoto, Isamu, Yamanaka, Takeharu, Nakagawa, Kazuhiko, Nakanishi, Yoichi
التنسيق: Artigo
اللغة:Inglês
منشور في: BioMed Central 2012
الموضوعات:
Study Protocol
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC3500214/
https://ncbi.nlm.nih.gov/pubmed/22849580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-12-327
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة